Canoe Financial Establishes At-The-Market Equity Program

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
69
Canoe Financial Establishes At-The-Market Equity Program for Canoe EIT Income Fund

Not for distribution to U.S. Newswire Services or for dissemination in the United States.

CALGARY, Alberta, July 26, 2019 (GLOBE NEWSWIRE) -- Canoe EIT Income Fund (the “Fund”) (TSX: EIT.UN) (TSX: EIT.PR.A) (TSX: EIT.PR.B) is pleased to announce that it has established an at-the-market equity program (“ATM Program”) that allows the Fund to issue up to $129,000,000 of Units of the Fund (the “Units”) to the public from time to time, at Canoe Financial LP’s discretion. Any Units sold in the ATM Program will be sold through the Toronto Stock Exchange (the “TSX”) or any other marketplace in Canada on which the Units are listed, quoted or otherwise traded at the prevailing market price at the time of sale.

The volume and timing of distributions under the ATM Program, if any, will be determined at Canoe Financial LP’s sole discretion. The ATM Program will be effective until November 25, 2020 unless terminated prior to such date by the Fund. The Fund intends to use the proceeds from the ATM Program in accordance with the investment objectives and investment strategies of the Fund, subject to the investment restrictions of the Fund.

The Fund’s regular monthly distribution of $0.10 per unit for unitholders of EIT.UN units remains unchanged. The Fund has maintained the $0.10 per unit monthly distribution since August 2009, through varying market conditions. The Fund’s annual voluntary redemption feature for unitholders of EIT.UN units also remains unchanged.

Sales of the Units through the ATM Program will be made pursuant to the terms of an equity distribution agreement dated July 26, 2019 (the “Equity Distribution Agreement”) with National Bank Financial Inc. (the “Agent”).

Sales of Units will be made by way of “at-the-market distributions” as defined in National Instrument 44-102 Shelf Distributions on the TSX or on any marketplace for the Units in Canada. Since the Units will be distributed at the prevailing market prices at the time of the sale, prices may vary among purchasers during the period of distribution. The ATM Program is being offered pursuant to a prospectus supplement dated July 26, 2019 to the Fund’s short form base shelf prospectus dated October 25, 2018. Copies of the prospectus supplement and the short form base shelf prospectus may be obtained from your registered financial advisor using the contact information for such advisor, or from representatives of the Agent and are available on SEDAR at www.sedar.com .

The Units have not been, nor will be, registered under the United States Securities Act of 1933, as amended, or any state securities laws and may not be offered or sold in the United States or to U.S. persons absent registration or applicable exemption from the registration requirement of such Act and applicable state securities laws. This news release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification under the securities laws of any such jurisdiction.

About the Fund

The Fund is one of Canada's largest, diversified closed-end investment funds and is listed on the TSX under the symbol EIT.UN. The Fund is actively managed and invests in a diversified portfolio of income-generating and capital growth-oriented securities listed primarily on the TSX. The Fund is designed to maximize distributions and net asset value for the benefit of its unitholders. The Fund is managed by Robert Taylor, Senior Vice President and Portfolio Manager of Canoe Financial LP.

About Canoe Financial LP

Canoe is one of Canada’s fastest growing independent mutual fund companies managing over $5.8 billion in assets across a diversified range of award-winning mutual funds and private energy equity products. Founded in 2008, Canoe Financial LP is an employee-owned investment management firm focused on building financial wealth for Canadians. Canoe has offices in Calgary, Toronto, Vancouver, Winnipeg, Ottawa and Montreal.

For further information, please contact: Investor Relations Canoe Financial LP 1-877-434-2796 www.canoefinancial.com   info@canoefinancial.com

Forward Looking Statement : Certain statements included in this news release constitute forward looking statements which reflect Canoe Financial LP’s current expectations regarding future results or events. Words such as “may,” “will,” “should,” “could,” “anticipate,” “believe,” “expect,” “intend,” “plan,” “potential,” “continue” and similar expressions have been used to identify these forward-looking statements. In addition, any statement regarding future performance, strategies, prospects, action or plans is also a forward-looking statement. Market predictions and forward-looking statements are subject to known and unknown risks and uncertainties and other factors that may cause actual results, performance, events, activity and achievements to differ materially from those expressed or implied by such statements. Forward looking statements involve significant risks and uncertainties and a number of factors could cause actual results to materially differ from expectations discussed in the forward looking statements including, but not limited to, changes in general economic and market conditions and other risk factors. Although the forward-looking statements are based on what Canoe Financial LP believes to be reasonable assumptions, we cannot assure that actual results will be consistent with these forward-looking statements. Investors should not place undue reliance on forward-looking statements. These forward-looking statements are made as of the current date and we assume no obligation to update or revise them to reflect new events or circumstances. 

The Fund makes monthly distributions of an amount comprised in whole or in part of return of capital (ROC) of the net asset value per unit. A ROC reduces the amount of your original investment and may result in the return to you of the entire amount of your original investment. ROC that is not reinvested will reduce the net asset value of the Fund, which could reduce the Fund’s ability to generate future income. You should not draw any conclusions about the Fund’s investment performance from the amount of this distribution.

Commissions, trailing commissions, management fees and expenses all may be associated with investment funds. Please read the information filed about the Fund on www.sedar.com before investing. The indicated rates of return are the historical and annual compounded total returns including changes in unit value and reinvestment of all distributions and do not take into account sales, redemption, distribution, or optional charges or income taxes payable by any security holder that would have reduced returns. Investment funds are not guaranteed and past performance may not be repeated.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Amplifon Data Breach Spurs Legal Scrutiny for Millions

Updated Category News Views 446

Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...

Continue Reading
Antengene’s AnTenGager-D2 Advances in Cancer Treatment

Updated Category News Views 56

Antengene's AnTenGager-D2 Offers Fresh Hope Alright, let's dig into the latest buzz from the 2026 Society for Immunotherapy of Cancer conference about Antengene's AnTenGager-D2 platform. If you're not into biotech lingo, buckle up, because this is a ride into the future of cancer treatments—where science fiction might soon become science fact. A Novel Approach to Tumor...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 344

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
Webull Faces Class Action Suit: Key Deadlines Loom

Updated Category News Views 250

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

Continue Reading
Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Updated Category News Views 333

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

Continue Reading
LG's ASIL D Certification: A Game Changer in Autos

Updated Category News Views 38

Why LG's ASIL D Certification Matters There ain't much in the tangled mess of automotive innovations these days that'll make a seasoned investor raise an eyebrow, but here comes LG Electronics grabbing the ASIL D certification like it's a badge of market honor. The ISO 26262 ASIL D is no walk in the park, folks—it's the top rung on the safety ladder, something that's...

Continue Reading
GlycoNex Eyes Japanese Market with Denosumab Biosimilar

Updated Category News Views 90

A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...

Continue Reading
Gildan's Crisis: Investors Face Losses Amid Lawsuit

Updated Category News Views 245

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

Continue Reading
FFR's OmniMind Takes Top Spot In RoboColiseum Rankings

Updated Category News Views 104

The AI Race Heats Up with FFR's Big Win Stop the presses—FFR's OmniMind AI just snagged the top spot on RoboColiseum's global rankings. Yeah, you heard right, this ain't just some run-of-the-mill news. As of November 6, they've parked themselves in pole position, beating out heavyweights like NVIDIA's GR00T N1.7 and GPT-6 Astra. That's like hitting a grand slam right...

Continue Reading
Intelligent Communication Forum Eyes Global Ecosystem Shift

Updated Category News Views 612

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Continue Reading

Top 5 Most Recently Viewed Articles

SOCi's AI Marketing: Leading G2's Summer 2026 Rankings

Updated Category News Views 12

AI's Rising Star in Enterprise Marketing Here's a tidbit worth chewing over your morning coffee: SOCi Inc., a name that's been buzzing in the enterprise circles, has nailed top spots in G2's Summer 2026 Report. We're talking about leading the charge in AI marketing and localized visibility, territories tough to crack unless you've got serious chops. In a world where...

Continue Reading
AI and the Future of Staffing: A Market Growth Story

Updated Category News Views 344

AI and the Future of Staffing: A Growth Story The staffing services market is on the verge of a major transformation, thanks in large part to advancements in Artificial Intelligence (AI). This evolution is projected to add an astounding USD 236.6 billion to the global staffing services market between 2024 and 2028. During this time, the market is expected to experience a...

Continue Reading
Optical Innovations Unite: OCC and Lightera's New Partnership

Updated Category News Views 317

Strategic Collaboration Between OCC and Lightera Optical Cable Corporation (NASDAQ: OCC) and Lightera, LLC are entering a significant partnership aimed at enhancing their product offerings primarily in the data center and enterprise sectors. This collaboration builds upon their long-term relationship, combining their strengths to create innovative optical connectivity...

Continue Reading
INFINOX Welcomes Artem Gonov as New Chief Technology Officer

Updated Category News Views 148

INFINOX Appoints Artem Gonov as Chief Technology Officer INFINOX, a globally recognized brokerage, has recently appointed Artem Gonov as its new Chief Technology Officer (CTO). This strategic move underlines the company's commitment to enhancing its technology landscape and providing exceptional platforms for its clients. Artem Gonov's Background and Expertise Mr. Gonov...

Continue Reading
George Medicines’ GMRx2 Sets New Standard for Hypertension Care

Updated Category News Views 126

George Medicines Introduces GMRx2 for Hypertension Management Recent findings published in The Lancet highlighted the promising results of a Phase III trial for GMRx2, a novel triple combination pill aimed at managing hypertension. Developed by George Medicines, this medication is making waves in the field of cardiovascular care as it demonstrates significant advancements...

Continue Reading